Terumo’s agreement to acquire OrganOx clearly shows the pattern. OrganOx spun out of the University of Oxford in 2008, and its liver perfusion platform has supported more than 5,000 liver transplants. Tokyo-based Terumo agreed to buy the company in August 2025 in a $1.5 billion deal.
Part of a Broader Pattern
An analysis of European medtech acquisitions since January 2025, drawn from Compass AI data, shows that many of the region’s most strategic technologies are being bought by acquirers based outside Europe. For European founders, investors, and corporate development teams, the question is less whether Europe can build valuable medtech companies and more who captures the value.
Who Has Been Buying
Recent examples include Medtronic’s acquisition of CathWorks, Boston Scientific’s purchase of SoniVie, Edwards Lifesciences’ acquisition of Vectorious, Olympus’ acquisition of BioProtect, RadNet’s purchase of France-based Gleamer, and Artivion’s acquisition of Endospan.
There are exceptions. France’s bioMérieux acquired Norway’s SpinChip, a reminder that European strategics are still buying, even if they have been less visible in the largest cross-border deals.
Israel’s Outsized Role
CathWorks, SoniVie, Vectorious, BioProtect, and Endospan all have Israeli roots, and most sit in cardiovascular and vascular categories that remain high priorities for large device companies.
The lesson is that clinical focus and strategic relevance drive acquisition decisions. Geography shapes where innovation starts, but strategic value decides who ends up owning it.
Investment Is Becoming More Selective
Acquisitions are only one sign of change in European medtech. Venture financing is also concentrating on companies with clinical validation, regulatory progress, early commercial traction, or clear strategic scale.
Public Capital Fills the Gaps
As private investors grow more selective, public and state-backed institutions remain important sources of medtech financing in Europe.
The European Innovation Council (EIC) Fund has been among the most active participants in recent European medtech rounds, alongside private investors such as Sofinnova Partners.
Other frequent participants include Bpifrance, Invest-NL, Panakès Partners, Wellington Partners, Atlantic Bridge, BOM, SFC Capital, and Supernova Invest.
The European Investment Bank (EIB) adds growth capital, backing companies such as Precisis, Xeltis, SamanTree Medical, and TISSIUM as they pursue regulatory approval, scale manufacturing, and commercialization.
For founders, public capital can bridge the costly stretch between early innovation and market entry, complementing rather than replacing private venture investment.
Funding and M&A Point to the Same Categories
The categories drawing investment mirror those drawing buyers. Cardiovascular and vascular deals include CathWorks, SoniVie, and Endospan. Imaging and diagnostics deals include RadNet’s acquisition of Gleamer, GE HealthCare’s deal for icometrix, and QuidelOrtho’s acquisition of LEX Diagnostics.
That overlap matters because today’s funded companies are tomorrow’s acquisition targets: clinical area, regulatory progress, technical differentiation, and commercial traction shape which ones get there.
Tracking that pipeline early gives investors and strategics a head start on where future deals are likely to happen. Compass AI is built for that kind of monitoring; book a demo to see the European deal data behind this analysis.
The Value-Capture Question for Europe
The pattern is consistent: Europe produces medtech companies with strong clinical and commercial potential, but many of the buyers are headquartered elsewhere.
Acquirers in the period analyzed included Medtronic, Boston Scientific, Edwards Lifesciences, Olympus, Terumo, RadNet, QuidelOrtho, Artivion, GE HealthCare, and Johnson & Johnson. Large European strategics were comparatively rare.
Europe clearly has the research base, founders, clinical networks, and innovation infrastructure to build valuable medical technologies. The open question is whether it can scale more of those companies itself and keep more of the value to reinvest in the next generation.
Key Takeaways
- Many of the largest recent acquisitions of European and Israeli medtech companies were made by buyers based outside Europe.
- Cardiovascular, vascular, imaging and diagnostics, AI and software, neuro, and oncology are drawing the most strategic interest.
- Investors are concentrating capital on companies with clinical validation, regulatory progress, differentiated technology, and commercial traction.
- Public and state-backed funders such as the EIC Fund, Bpifrance, and the EIB continue to bridge financing gaps.
- Europe’s challenge is not creating value but capturing it.
The European medtech market is becoming more selective and more international. Companies with strong evidence, clear regulatory pathways, and differentiated technology are best placed to attract capital and buyers. Book a Compass AI demo to track the companies, investors, and acquirers shaping these deals.
